Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant can be used for psoriasis research
In Vitro
The transcription factor retinoic acid-related orphan receptor gamma t (RORγt) has been identified as the master regulator of TH17 cell differentiation and IL-17/22 production and is therefore an attractive target for the treatment of inflammatory diseases. Cedirogant (ABBV-157) has the potential for chronic plaque psoriasis research. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:RORγt
사양
사양 및 순도
10mM in DMSO
생화학 및 생리적 메커니즘
Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant can be used for psoriasis research.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.